ORAL PRESENTATION

Open Access

Myocardial fibrosis as a early cardiac marker of disease in patients with lamin A/C mutations

Andrea Barison^{1*}, Pier G Masci², Marianna Fontana², Matteo Milanesi², Roberta Poletti², Vincenzo Positano², Claudio Passino¹, Giovanni D Aquaro², Giancarlo Todiere², Michele Emdin², Massimo Lombardi²

From 2011 SCMR/Euro CMR Joint Scientific Sessions Nice, France. 3-6 February 2011

Objective

to assess myocardial fibrosis in lamin A/C mutations (LM) carriers using constrast-enhanced cardiac magnetic resonance (CMR).

Background

LM carriers usually develop a dilated cardiomyopathy (DCM) phenotype in association with atrio-ventricular blocks and/or ventricular arrhythmias. However, sudden cardiac death may be the first clinical manifestation. Hence early detection of myocardial abnormalities before overt left ventricular (LV) dysfunction is warranted for a better risk stratification.

Methods

Seventeen paucisymptomatic LM carries (age 41±16 years, 9 male), 14 paucisymptomatic DCM patients (age 59±11 years, 8 male, NYHA I-II) with mild LV dysfunction (ejection-fraction 40%-55%) and 12 healthy controls (age 46±10 years, 9 male) underwent complete clinical, echocardiographic, biohumoral and contrast-enhanced CMR assessment. Cine CMR was used to derive LV volumes, mass and function, and post-contrast CMR to detect late gadolinium enhancement (LGE) as an index of gross fibrosis. Eight LM patients, all DCM patients and all normal controls underwent pre- and post-contrast myocardial T1 mapping with gadolinium partition coefficient calculation, as an index of interstitial fibrosis.

Results

LM carriers presented a similar LV end-diastolic volume $(85\pm17 \text{ ml/m2}, p=NS)$ and slightly reduced ejection-fraction $(61\pm6\% \text{ p}<0.001)$ than controls $(83\pm19 \text{ ml/m2},$

ls (83±19 ml/m2, doi:10.1186

Full list of author information is available at the end of the article

Published: 2 February 2011

Conclusions

Author details

doi:10.1186/1532-429X-13-S1-O76

only slightly higher than controls.

Cite this article as: Barison *et al.*: Myocardial fibrosis as a early cardiac marker of disease in patients with lamin A/C mutations. *Journal of Cardiovascular Magnetic Resonance* 2011 **13**(Suppl 1):076.

67±6%), while in DCM patients LV end-diastolic volume

(102±17 ml/m2) and ejection-fraction (49±5%) were worse

than both controls and LM carriers (p<0.001). Moreover,

DCM patients presented worse diastolic dysfunction (9±3 vs 7±1, p<0.01), NT-proBNP plasma levels (438±416 vs

108±139 ng/l, p<0.01) and Doppler-estimated pulmonary

pressure (33±7 vs 30±5 mmHg, p<0.01) than LM carriers.

Six (43%) DCM patients presented DE, representing 9±3%

of LV mass; similarly, seven (42%) LM carriers had DE,

but with a larger extension (11 \pm 5% of LV mass, p<0.03).

In LM carries DE distribution was patchy (2 pts) or mid-

wall (5 pt), similarly to DCM patients (patchy in 1 pt, mid-

wall in 4 pts, subendocardial in 1 pt). GPC reached a steady state 5 minutes after gadolinium injection. In DCM

patients GPC was slightly higher than controls $(0.42\pm0.05 \text{ vs } 0.38\pm0.06, \text{ p=}0.04)$, while in LM carriers it was much

higher (0.45±0.07) than controls (p<0.01). Even excluding

hyperenhanced myocardium, in LM carriers GPC

remained higher than controls, while in DCM patients

Myocardial fibrosis occurs early in LM carrier before LV

dilatation and dysfunction and may represent an early

¹Scuola Superiore Sant'Anna and Fondazione G Monasterio CNR - Regione Toscana, Pisa, Italy. ²Fondazione G. Monasterio CNR - Regione Toscana, Pisa, Italy.

phenotypic expression of cardiac involvement.



